Answers are grounded in this paper and cite their sources.
Although N 6 -adenosine methyltransferase (METTL3) is frequently upregulated in breast cancer patients, the anticancer effect of small-molecule inhibitors targeting METTL3 has not yet been studied.The present study aimed to investigate the anti-tumorigenic effects of STM2457, a METTL3 inhibitor, on a panel of breast cancer cells representing distinct clinical subtypes.Measurement of cell viability using MTT assay demonstrated dose-and time-dependent reduction in viability in MCF7, SKBR3, and MDA-MB-231 cells, which are representative of luminal A, HER2-positive, and triple-negative breast cancer subtypes, respectively.Immunoblotting analysis revealed that STM2457 induced pro-apoptotic effects in breast cancer cells, as evidenced by the cleaved poly (ADP-ribose) polymerase (PARP) and caspase-3.In addition, analysis of cell cycle distribution with flow cytometry revealed that it induced cell cycle arrest at G0/G1-phase.Consistently, treatment with STM2457 increased the Annexin V-stained cell population, corroborating the pro-apoptotic effects of the compound.Moreover, analysis of colonies formed by breast cancer cells in a soft agar matrix showed that STM2457 reduced the anchorage-independent growth of breast cancer cells, suggesting its potential to inhibit colony formation.Together, these findings indicate that STM2457 exerts cytotoxic and pro-apoptotic effects in breast cancer cells.Our study demonstrates the therapeutic potential of METTL3 inhibitor STM2457 in treating breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Shrestha et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: